Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).

As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lucid reports Q2 output, names new CFO and five other leaders
• Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy